350 rub
Journal Technologies of Living Systems №8 for 2009 г.
Article in number:
MOLECULAR-GENETIC ANALYSIS OF PLATELET ADP-RECEPTORS IN HEALTHY DONORS AND PATIENTS TREATED WITH CLOPIDOGREL
Keywords: platelet ADP-receptors P2Y12 P2Y1 gene expression CYP 3A4 CYP 3A5 CYP 2C19 clopidogrel
Authors:
O.V. Sirotkina, N.A. Bogankova, A.E. Taraskina, E.L. Zheleznyak, S.A. Boldueva, T.V. Vavilova
Abstract:
Modern study of platelet haemostasis has shown that only the complex genetic, pharmacogenetic and functional researches with molecular techniques are effective in revealing individual sensitive factors to antiaggregant therapy and platelet-s reactivity. The platelet-s adhesion, activation and aggregation play key role in haemostasis. Particular attention is given to ADP-receptors P2Y1 and P2Y12. The aim of this work is to analyze different genetic variants and expressions of platelet re-ceptors P2Y1 and P2Y12 in healthy persons and STEMI patients treated with clopidogrel. To eva-luate clopidogrel-s efficacy in cardiovascular disease the mutations of cytochrome P-450 have been investigated too. The obtained results have shown that genetic variants P2Y12 and P2Y1 were not associated with individual sensitivity to clopidogrel. The cytochrome P-450 polymorphisms did not seem to be responsible for antiplatelet therapy substantially. The level of gene expression P2Y12 was significantly higher than the level of gene expression P2Y1. The correlation between P2Y12 expression, individual-s age and functional platelet activity was recovered for first time. The P2Y1 gene expression did not distinguish in patients with positive and negative response to clopidogrel. Whereas P2Y12 gene expression was higher in patients non-responded to clopidogrel compared with responded patients. Consequently, this finding will be considered as prognostic factor for clopidogrel-s efficacy in cardiovascular disease.
Pages: 46-52
References
  1. Gachet C., Hechler B.The platelet P2 receptors in thrombosis // Seminars in Thrombosis and Haemostasis. 2005. V. 31. № 2. P.162-167.
  2. Murugappan S., Kunapuli S.The role of ADP receptors in platelet function // Frontiers in Bioscience. 2006. V.11. P. 1977-1986.
  3. Storey R., JudgeH., Heptinstall S.Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin // Thromb. Haemost. 2002. V. 88. № 3. P. 488-494.
  4. Ferguson A., Dokainish H., Lakkis N. Aspirin and clopidogrel response variability // Tex. Heart. Inst. J. 2008. V. 35. № 3. P. 313-320.
  5. Michelson A. P2Y12 antagonism: promises and challenges // Artherioscler. Thromb. Vasc. Biol. 2008. V. 28. P. s33-s38.
  6. Oestreich J., Smyth S., Campbell C. Platelet function analisis: at the edge of meaning // Thromb. Haemost. 2009. V. 101. P. 217-219.
  7. Сироткина О.В., Заботина А.М., Беркович О.А., Баженова Е.А., Вавилова Т.В., Шварцман А.Л.. Генетические варианты АДФ-рецептора тромбоцитов P2Y12, ассоциированные с изменением функциональной активности тромбоцитов и развитием сердечно-сосудистых заболеваний // Генетика. 2009. Т. 45. № 2. С. 247-253.
  8. Hettherington S., Singh R., Lodwick D., Thompson J., Goodall A., Samani N. Dimorphism in the P2Y12 ADP receptor gene is associated with increased platelet activation response to ADP // Artherioscler. Thromb. Vasc. Biol. 2005. V. 25. P. 252-257.
  9. Smith S., Judge H., Peters G., Armstrong M., Fontana P., Gaussem P., Daly M., Storey R. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the inhibitory effects of clopidogrel therapy // Platelets. 2006. V. 17. P. 250-258.
  10. van Schaik R., de Wildt S., van Iperen N., Uitterlin den A., van den Anker J., Lindemans J. CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians // Clinical Chemistry. 2000. V. 46. P. 1834-1836.
  11. Hulot J., Bura A., Villard E., Azizi M., Remones V., Goyenvalle C., Aiach M., Lechat P., Gaussem P. Cytochrome P450 2C19 loss-of function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects // Blood. 2006. V. 108. P. 2244-2247.
  12. Wang L., Karlsson L., Moses S., Hultgardh-Nilsson A., Andersson M., Borna C., Gudbjartsson T., Jern S., Erlinge D. P2 receptor expression profiles in human vascular smooth muscle and endothelial cells // J. Cardiovasc. Pharmacol. 2002. V. 40. № 6. P. 841-853.
  13. Czermak C., Lehofer M., Wagner E., Prietl B., Lemonis L., Rohrhofer A., Schanenstein K., Liebmann P.Reduced dopamine D4 receptor mRNA expression in lymphocytes of long-term abstinent alcohol and heroin addicts // Addiction. 2004. V. 99. P. 251-257.
  14. Meadows T., Bhatt D. Clinical aspects of platelet inhibitors and thrombus formation // Circ. Res. 2007. V. 100. P. 1261-1275.
  15. Angiolillo D., Fernandez-Ortiz A., Bernardo E., Ramirez C., Cavallari U., Trabetti E., Sabate M., Jimenez-Quevedo P., Hernandez R., Moreno R., Escaned J., Alfonso F., Banuelos C., Costa M., Bass T., Pignatti P., Macaya C. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease // Thrombosis Research. 2005. V. 116. P. 491-497.
  16. Gachet C.P2 receptors, platelet function and pharmacological implications // Thromb. Haemost. 2008. V. 99. P. 466-472.
  17. Frere C., Cuisset T., Morange P., Quilici J., Camoin-Jau L., Saut N., Faille D., Lambert M., Juhan-Vague I., Bonnet J., Alessi M. Effect of cytochrome p450 polymor­phisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome // Am. J. Cardiol. 2008. V. 101. № 8. P. 1088-1093.
  18. Angiolillo D., Fernandez-Ortiz A., Bernardo E., Ramirez C., Cavallari U., Trabetti E., Sabate M., Hernandez R., Moreno R., Escaned J., Alfonso F., Banuelos C., Costa M., Bass T., Pignatti P.F., Macaya C. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel // Arterioscler. Thromb. Vasc. Biol. 2006. V. 26. P. 1895-1900.
  19. Lau W., Gurbel P., Watkins p., Neer C., Hopp A., Carville D., Guyer K., Tait A., Bates E. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel
    resistance // Circulation. 2004. V. 109. P. 166-171.
  20. Malek L., Kisiel B., Spiewak M., Grabowski M., Filipiak K., Kostrzewa G., Huczek Z., Ploski R., Opolski G. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel // Circ. J. 2008. V. 72. P. 1165-1169.
  21. Wang L., Ostberg O., Wihlborg A.-K., Brogren H., Jern S., Erlinge D. Quantification of ADP and ATP receptor expression in human platelets // J. Thromb. Haemost. 2003. V. 1. P. 330-336.
  22. O-Braun O., Amisten S., Wihlborg A.-K., Hunting K., Nillson D., Erlinge D. Residual platelet ADP reactivity after clopidogrel treatment is dependent on activation of both the unblocked P2Y1 and the P2Y12 receptor and is correlated with protein expression of P2Y12 // Purinergic Signalling. 2007. V. 3. P. 195-201.